(Q39880598)

15 September 2017

title

Refocusing the war on cancer: the critical role of personalized treatment (English)

1 reference

15 September 2017

Anil Potti

1

1 reference

15 September 2017

Richard L Schilsky

series ordinal

2

1 reference

15 September 2017

Joseph R Nevins

series ordinal

3

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

Science Translational Medicine

15 September 2017

published in

1 reference

15 September 2017

volume

2

1 reference

15 September 2017

issue

28

1 reference

15 September 2017

page(s)

28cm13

1 reference

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

Genomic signatures to guide the use of chemotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000643

10.1126/SCITRANSLMED.3000643

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference